TCI Wealth Advisors’s ImmunityBio IBRX Stock Holding History

TCI Wealth Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,215	Closed	-$4.03K	–	1129
2023 Q1	$4.03K	Buy	2,215 +2,163	+4,160%	+$6.72K	﹤0.01%	1684
2022 Q4	$264	Buy	52 +2	+4%	+$11	﹤0.01%	2304
2022 Q3	$0	Hold	50	–	–	﹤0.01%	2401
2022 Q2	$0	Hold	50	–	–	﹤0.01%	2385
2022 Q1	$0	Hold	50	–	–	﹤0.01%	2320
2021 Q4	$0	Buy	+50	New	+$376	﹤0.01%	2392
2019 Q2	–	Sell	-75	Closed	–	–	1480
2019 Q1	$0	Hold	75	–	–	﹤0.01%	1464
2018 Q4	$0	Buy	+75	New	+$172	﹤0.01%	1524
2016 Q4	–	Sell	-100	Closed	-$1K	–	1405
2016 Q3	$1K	Sell	100 -100	-50%	-$747	﹤0.01%	1134
2016 Q2	$1K	Hold	200	–	–	﹤0.01%	1075
2016 Q1	$2K	Hold	200	–	–	﹤0.01%	947
2015 Q4	$3K	Hold	200	–	–	﹤0.01%	795
2015 Q3	$2K	Buy	+200	New	+$4.37K	﹤0.01%	793

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

TCI Wealth Advisors's IBRX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 2,215 shares — an estimated $4.03K sold.

TCI Wealth Advisors first reported a position in IBRX in Q3 2015 and held it in 13 quarters. The position peaked at $4.03K in Q1 2023. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

TCI Wealth Advisors reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 2,215 ImmunityBio shares in Q2 2023, an estimated $4.03K.
TCI Wealth Advisors first reported a position in ImmunityBio in Q3 2015 and held it in 13 quarters.
TCI Wealth Advisors's ImmunityBio position peaked at $4.03K in Q1 2023.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.